Hypericin-PDT responses depend on the drug and light conditions. In A549 cells, liproxstatin-1 rescued viability after 2 μM hypericin with 2 min irradiation, but not after 125 nM with 30 min irradiation or 10 μM with 2 min irradiation. Pan-caspase inhibitor rescue in the low-concentration regime further limits a universal ferroptosis interpretation. [1]
Light-condition dependence of inhibitor rescue in A549 cells
Cell-based study · Human lung adenocarcinoma A549 cells [1]
Liproxstatin-1 rescued viability after the intermediate hypericin/light condition but not the lower-concentration/longer-light or higher-concentration conditions. Pan-caspase inhibitor rescue was seen in the low-concentration regime. These findings limit any single cell-death mechanism to its treatment context.
Literature-Reported Treatment Conditions
- Treatment concentration
- 125 nM, 2 μM or 10 μM hypericin; liproxstatin-1 concentration-response comparison.
- Exposure duration
- 4 h dark loading; irradiation 30 min for 125 nM, 2 min for 2 μM and 10 μM; viability typically 24 h after irradiation.
- Method
- Red light from xenon arc lamp, 600 nm band filter, 1.5 mW/cm²; CCK-8 viability normalized to DMSO vehicle.
- Vehicle
- DMSO; final concentration not specified in the read methods.
- Co-treatment
- Light activation; inhibitor cotreatments tested as mechanistic controls.
- Reported limits
- No IC50 estimated here; exact plotted percentages were not extracted.
Methods and source locations
Compound reported in the paper: Hypericin; Compound label in the paper: HYP
Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.
Results 1.1; Figure 1b–d,f–g; Methods 3.1–3.2, 3.19
A549 cell viability after hypericin/light with liproxstatin-1: CCK-8; viability measured typically 24 h post-light, three independent replicates; no graph-derived decimals. — Figure 1b; Results 1.1; Methods 3.2
A549 low-concentration phototoxicity with pan-caspase inhibitor: CCK-8; Figure 1c concentration series and Figure 1d intermediate-condition controls. — Figure 1c–d; Results 1.1
Lipid peroxidation and GPXs activity after hypericin photoactivation
Cell-based study · Human lung adenocarcinoma A549 cells and lysates from treated cells [1]
Under the 2 μM/2 min PDT condition, lipid oxidation increased and GSH decreased; liproxstatin-1 opposed these changes. A separate lysate readout within this redox assessment showed no significant decrease in aggregate GPXs activity at 8 h relative to control, unlike RSL3. The assay does not establish direct GPX4 inhibition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 2 μM hypericin; liproxstatin-1 8 μM for Figure 2a,f–g; comparator RSL3 10 μM.
- Exposure duration
- 4 h dark loading, 2 min red light; Figure 2a,f and S7b at 8 h post-light; Figure 2h follows lipid oxidation for 0–120 min.
- Method
- 600 nm band-filtered xenon light, 1.5 mW/cm²; GSH assay, MDA assay, C11-BODIPY oxidation and lysate peroxide-reduction activity assay.
- Vehicle
- DMSO vehicle control; Figure 2b separately labels HYP-dark and HYP-PDT.
- Co-treatment
- Light activation; liproxstatin-1 and RSL3 used in specified comparison groups.
- Reported limits
- GPXs activity is an aggregate lysate readout, not an isolated purified GPX4 binding or enzyme-selectivity assay.
Methods and source locations
Compound reported in the paper: Hypericin; Compound label in the paper: HYP
Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.
Results 1.1–1.2; Figure 2a–b,f–h; Supplementary Figure S7b–c; Methods 3.2, 3.7–3.8, 3.10–3.11, 3.19
Lipid peroxidation and reduced glutathione after PDT: GSH/GSSG kit, MDA assay and C11-BODIPY flow cytometry; qualitative extraction only. — Figure 2a,f–h; Results 1.1–1.2; Methods 3.7, 3.10–3.11
Peroxide-reducing GPXs activity in A549 lysates 8 h after PDT: Lysate assay monitors NADPH absorption at 340 nm with cumene hydroperoxide substrate; S7b, mean ± SD, n=3 biologically independent samples. — Supplementary Figure S7b and caption; Methods 3.8; Results 1.1
GPX4 overexpression rescue of hypericin-PDT responses
Cell-based study · Human cholangiocarcinoma HUCCT1 and CCLP1 cells [2]
GPX4 overexpression opposed the reduction in viability and increased ROS signal caused by hypericin-PDT, relative to vector controls. This supports a GPX4-associated protective response in these cell lines without demonstrating direct hypericin binding to GPX4.
Literature-Reported Treatment Conditions
- Treatment concentration
- Rescue-panel hypericin concentration is not specified in the retrieved Figure 4E–F legend/Results; Figure 4A–D context uses 0, 1, 2 and 4 μM. All panels label HY-PDT at 1 J/cm².
- Exposure duration
- 4 h dark loading; CCK-8 viability typically 24 h after irradiation.
- Method
- PBS wash after loading; 650 nm light, 1 J/cm²; vector versus GPX4-overexpression comparisons, CCK-8 and DCFH-DA fluorescence.
- Vehicle
- Hypericin vehicle not specified in the retrieved main methods.
- Co-treatment
- Light activation; GPX4 overexpression is a genetic rescue condition, not a second drug.
- Reported limits
- Hypericin concentration for Figure 4E–F, detailed transfection timing and ROS post-light collection time are not specified in the retrieved main text/legend. Do not borrow 2 μM from Figure 5. DCFH-DA is not lipid-peroxide-specific.
Methods and source locations
Compound reported in the paper: Hypericin; Compound label in the paper: HY
Applies to the reported hypericin preparation and model under the specified light treatment; does not establish catalog-lot performance or clinical efficacy.
Results “HY-PDT triggers ferroptosis regulated by GPX4 in CCA cells”; Figure 4E–F (context A–D); Materials and methods reagent table, HY-PDT/viability and ROS methods
Viability after HY-PDT in vector and GPX4-overexpressing cells: CCK-8 absorbance at 450 nm; vector and overexpression-only controls included. — Figure 4E; associated Results; HY-PDT treatment and cell viability assay
DCFH-DA ROS signal after HY-PDT: Representative fluorescence images; no fluorescence magnitude inferred. — Figure 4F; associated Results; Reactive oxygen species detection